Home
-
Novo Nordisk Announces Restructuring; Cutting 11% of Workforce
In his first major move since taking the helm of Novo Nordisk last month, Mike Doustdar, President and CEO, announced a restructuring plan as the company lowers its sales & profit outlook. What’s behind the move?
-
CDMO/CMO Report: Tracking Expansions for Injectables
Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. DCAT Value Chain Insights rounds up the latest expansions.
-
Executive Insights: What’s Next for Novo Nordisk?
With new CEO Maziar Mike Doustdar taking the helm, Novo Nordisk is looking to expand its obesity franchise, with an oral version of it blockbuster weight-loss drug, Wegovy (semaglutide). Will that be the key to changing the fortunes of the company?
DCAT MEMBER COMPANY COMMUNITY
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
ICYMI: DCAT Production to Prescription Podcast: “Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?”
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, a key…
-
DCAT Awards Grants To Student Scientists at the 2025 Regeneron International Science & Engineering Fair
The Drug, Chemical & Associated Technologies Association (DCAT) has awarded $30,000 in grants to student scientists of four projects who participated in the Regeneron International Science & Engineering Fair (Regeneron…
